Suzano Secures All Antitrust Approvals for Kimberly-Clark Joint Venture
SUZ is trading near its 52-week low of $8.11 (3.3% above the low).
Summary
Suzano announced it has received all antitrust regulatory approvals for its joint venture with Kimberly-Clark, a key step towards closing the strategic acquisition of a majority stake in K-C's international tissue business.
Key Events · M&A and Partnerships · SUZ
-
Antitrust Approvals Secured
Suzano has obtained all required antitrust regulatory approvals for its acquisition of a 51% equity interest in a new company formed with Kimberly-Clark Corporation.
-
Strategic Joint Venture
The transaction involves a joint venture with Kimberly-Clark, where the new company will hold assets related to the manufacturing, marketing, and distribution of tissue products across various international regions.
-
Remaining Condition
The closing of the transaction is still subject to the completion of Kimberly-Clark's corporate reorganization in the included regions.
-
Expected Closing in Q3 2026
Suzano continues to expect the transaction to close in the third quarter of 2026, as previously disclosed.
Analysis · SUZ · Manufacturing
Suzano has cleared a major hurdle for its strategic joint venture with Kimberly-Clark by obtaining all necessary antitrust regulatory approvals. This de-risks the transaction significantly, moving it closer to completion. The deal will give Suzano a 51% equity interest in a new company holding Kimberly-Clark's tissue product assets across South America, Central America, Europe, Africa, the Middle East, Asia, and Oceania. This expansion into downstream tissue products represents a material strategic shift and growth opportunity for Suzano. The transaction remains subject to Kimberly-Clark's internal corporate reorganization, with closing still expected in the third quarter of 2026.
At the time of this filing, SUZ was trading at $8.38 on NYSE in the Manufacturing sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $8.11 to $11.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.